# A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Source: https://onco.cc/trials/nct06378177/  
OnCo record `nct06378177` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Toripalimab, Paclitaxel / nab-paclitaxel in head and neck squamous cell carcinoma, run by Lyvgen Biopharma Holdings Limited, active and no longer recruiting.

## Summary

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) is a phase 2 interventional study registered as NCT06378177 by Lyvgen Biopharma Holdings Limited, with 64 participants planned, started 2024-06-21 and due to reach its primary completion in 2027-10-31. Interventions recorded: LVGN6051 Monoclonal Antibody Injection, toripalimab Injection, Paclitaxel injection. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06378177
- Phase: 2
- Setting: A Phase 2 Study of LVGN6051 Combined With Toripalimab and Paclitaxel for Recurrent/Metastatic HNSCC Rapidly Progressed From Previous Platinum-containing Curative Treatment or Contraindicated for Platinum-containing Treatment
- Sponsor: Lyvgen Biopharma Holdings Limited
- Enrolled: 64

## Sources

- ClinicalTrials.gov NCT06378177: https://clinicaltrials.gov/study/NCT06378177

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [LVGN6051](https://onco.cc/drugs/lvgn6051/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Toripalimab](https://onco.cc/drugs/toripalimab/)

---
JSON: https://onco.cc/api/v1/entities/nct06378177.json